Welcome to our dedicated page for BMBIF news (Ticker: BMBIF), a resource for investors and traders seeking the latest updates and insights on BMBIF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BMBIF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BMBIF's position in the market.
Bright Minds Biosciences (Nasdaq: DRUG), a biotechnology firm, announced a symposium on May 19, 2022, focusing on Dravet Syndrome and therapeutic advancements. Key Opinion Leaders, including CEO Ian McDonald and experts from UCSF and Cook Children’s, will discuss BMB-101, the company's leading drug candidate for Dravet syndrome. Additionally, the company issued 100,000 restricted share units and 25,000 common shares to board members. BMB-101 is a selective 5-HT2C agonist, showing promise in treating neuropsychiatric disorders and addiction.
Bright Minds Biosciences announced a symposium for May 19, 2022, focusing on updates regarding BMB-101, its lead program for Dravet Syndrome treatment. Key speakers include CEO Ian McDonald and CMO Dr. Revati Shreeniwas. The event will feature expert discussions and a Q&A session. Additionally, the company has issued 60,000 RSUs related to consulting agreements and plans to issue 25,000 common shares, both subject to vesting and hold periods. Dravet Syndrome, affecting approximately 1:15,700 individuals in the U.S., represents a significant unmet medical need.
Bright Minds Biosciences (Nasdaq: DRUG) announced the successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101, with no major toxicological findings observed. Conducted by ITR Laboratories Canada, the studies confirmed that BMB-101 was well tolerated in both mice and dogs at doses of up to 40 and 30 mg/kg/day, respectively. The results support the forthcoming first-in-human clinical trial anticipated in Q2 2022. Dr. Revati Shreeniwas noted the potential of BMB-101 as a treatment for Dravet Syndrome, highlighting a significant unmet need in this area.
Bright Minds Biosciences (NASDAQ: DRUG) announced that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:00 PM ET. The presentation will focus on the company's work in developing novel treatments for neuropsychiatric disorders, epilepsy, and pain, particularly BMB-101. This selective serotonin agonist shows promise in treating conditions like Dravet syndrome and mental health disorders. An archived version will be available on the company’s website for 90 days post-conference.
Bright Minds Biosciences (BMB) announced a virtual presentation by CEO Ian McDonald and CSO Alan Kozikowski at the H.C. Wainwright Bioconnect Conference on January 10, 2022, starting at 7:00am ET. The presentation will cover their innovative drug development targeting neuropsychiatric disorders and epilepsy. The company is focused on advancing BMB-101, a selective serotonin receptor agonist, showing potential in treating addiction and impulsive behaviors. A replay of the presentation will be available on their website for 90 days after the event.
Bright Minds Biosciences (BMB) announced CEO Ian McDonald will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference on December 8, 2021, at 3:00 PM ET. The conference will feature a webcast, with an archived replay available on the company's website for 90 days. Bright Minds is focused on developing innovative treatments for neuropsychiatric disorders, epilepsy, and pain. Its investigational drug BMB-101 shows promise in treating conditions like Dravet syndrome and mental health disorders by targeting serotonin receptors involving crucial neurotransmitter pathways.
Bright Minds Biosciences (BMBIF, DRUG) announced significant advancements in its 5-HT2A psychedelic drug discovery program. The company has synthesized hundreds of novel compounds and aims to announce its lead molecule by Q1 2022. Utilizing advanced drug design and preclinical modeling, Bright Minds aims to develop safer, more potent treatments for neuropsychiatric disorders, including depression and PTSD. The potential market for mental health drugs is projected to grow from $37 billion in 2020 to $59 billion by 2031, highlighting a significant commercial opportunity for the company.
Bright Minds Biosciences (BMB) announced its common stock will be listed on the Nasdaq Capital Market under the ticker symbol 'DRUG' starting November 8, 2021. This listing is seen as a milestone, aiming to enhance shareholder returns and market presence. The company is advancing its lead drug candidate, BMB-101, targeting Dravet syndrome, with first-in-human trials expected in H1 2022. BMB focuses on innovative treatments for neuropsychiatric disorders, leveraging serotonin agonists to tackle difficult-to-treat conditions.
Bright Minds Biosciences Inc. (CSE: DRUG/OTCIQ: BMBIF) will present live at VirtualInvestorConferences.com on October 14, 2021, from 11:00 – 11:30 AM ET. CEO Ian McDonald and VP Josh Blacher will lead the presentation, allowing real-time investor interactions. For those unable to attend live, an archived webcast will be available post-event. Recent highlights include the advancement of BMB-101 to IND-enabling studies, significant seizure reduction by their proprietary 5-HT2C Agonist, and their application to list on Nasdaq.
Bright Minds Biosciences, a biotech firm specializing in treatments for neuropsychiatric disorders, epilepsy, and pain, announced a presentation at the LD Micro Main Event on October 12, 2021, at 12:30 PM PT. CEO Ian McDonald will lead the presentation, accessible via a webcast. Additionally, the management team will meet with institutional investors at the conference. Following the event, a replay of the presentation will be available on the company’s website for 90 days. Bright Minds aims to develop next-generation serotonin agonists with fewer side effects.
